Literature DB >> 11992241

Laboratory diagnosis of congenital von Willebrand disease.

Ulrich Budde1, Elke Drewke, Kerstin Mainusch, Reinhard Schneppenheim.   

Abstract

Von Willebrand disease (vWD) is caused by quantitative or qualitative defects, or both, of the von Willebrand factor (vWF), a multimeric high-molecular glycoprotein (GP). Typically, it affects the primary hemostatic system, which is reflected by a mucocutaneous bleeding tendency simulating a platelet function defect. The vWF promotes its function in two ways: (1) by supporting platelet adhesion to the injured vessel wall under conditions of high shear forces and (2) by its carrier function for factor VIIIc (FVIIIc) in plasma. Because of the complexity of the disease, diagnosis of vWD is one of the most challenging of any coagulation disorder. The stepwise diagnosis of vWD includes patients and family history, screening procedures (bleeding time [BT], filter tests, platelet counts, activated partial thromboplastin time [aPTT]), confirmatory tests (vWF antigen [vWF:Ag], vWF ristocetin cofactor activity [vWF:RCo], vWF collagen-binding [vWF:CB] assay, ristocetin-induced platelet aggregation [RIPA], FVIIIc) and tests for final classification (multimeric analysis, FVIII binding capacity of vWF [vWF:FVIIIB], platelet vWF). In 1999, we classified 303 patients with congenital vWD as type 1 (n = 122), type 2 (n = 171), and type 3 (n = 10). Type 2 was further subdivided into type 2A (n = 126), type 2B (n = 17), type 2M (n = 22), and type 2N (n = 6). Type 2A showed a remarkable heterogeneity, with only 27.8% (n = 36) of the "classic" IIA pattern. The other high-frequency patterns were type IB (25.4% n = 32) and type IIE/F/H-like structural abnormalities (28.6% n = 36). The spectrum was completed with samples from patients with types 2D, 2C, 2C Miami, smeary structures, and other rare subtypes (together 18.9% n = 23).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992241     DOI: 10.1055/s-2002-27820

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  8 in total

1.  Bleeding complications after arthroscopy in a JAK2V617F-positive patient with essential thrombocythemia and acquired von Willebrand syndrome (AVWS).

Authors:  Joanna Rupa-Matysek; Krzysztof Lewandowski; Maria Lewandowska; Ewelina Wojtasińska; Marzena Liliana Wojtaszewska; Michał Walczak; Ksenia Bykowska; Mieczysław Komarnicki
Journal:  Int J Hematol       Date:  2014-11-29       Impact factor: 2.490

2.  Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

Authors:  D M Larsen; S L Haberichter; J C Gill; A D Shapiro; V H Flood
Journal:  Haemophilia       Date:  2013-03-18       Impact factor: 4.287

3.  Turbulent Flow Promotes Cleavage of VWF (von Willebrand Factor) by ADAMTS13 (A Disintegrin and Metalloproteinase With a Thrombospondin Type-1 Motif, Member 13).

Authors:  Maria Bortot; Katrina Ashworth; Alireza Sharifi; Faye Walker; Nathan C Crawford; Keith B Neeves; David Bark; Jorge Di Paola
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-11       Impact factor: 10.514

Review 4.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.

Authors:  Marcus Stockschlaeder; Reinhard Schneppenheim; Ulrich Budde
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

5.  Rapid Restoration of Thrombus Formation and High-Molecular-Weight von Willebrand Factor Multimers in Patients with Severe Aortic Stenosis After Valve Replacement.

Authors:  Keigo Yamashita; Hideo Yagi; Masaki Hayakawa; Takehisa Abe; Yoshihiro Hayata; Naoko Yamaguchi; Mitsuhiko Sugimoto; Yoshihiro Fujimura; Masanori Matsumoto; Shigeki Taniguchi
Journal:  J Atheroscler Thromb       Date:  2016-04-05       Impact factor: 4.928

6.  Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center.

Authors:  Chatphatai Moonla; Benjaporn Akkawat; Yaowaree Kittikalayawong; Autcharaporn Sukperm; Mukmanee Meesanun; Noppacharn Uaprasert; Darintr Sosothikul; Ponlapat Rojnuckarin
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

7.  Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome.

Authors:  Masaki Hayakawa; Keisuke Takano; Michinori Kayashima; Kei Kasahara; Hidetada Fukushima; Masanori Matsumoto
Journal:  J Atheroscler Thromb       Date:  2020-10-28       Impact factor: 4.928

8.  von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.

Authors:  Naoto Nishigori; Masanori Matsumoto; Fumikazu Koyama; Masaki Hayakawa; Kinta Hatakeyayama; Saiho Ko; Yoshihiro Fujimura; Yoshiyuki Nakajima
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.